Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
EMPOWER-Lung 3
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
- NCT03409614 ↗
- Completed
- Regeneron Pharmaceuticals
- Deep
We haven't built an HCP commentary report on EMPOWER-Lung 3 (cemiplimab in first-line advanced or metastatic non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EMPOWER-Lung 3 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| Podcasts | 20 | |
| YouTube | 19 | |
| X threads | 15 |
The trial
ClinicalTrials.gov- Official title
- A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- REGN2810; REGN2810/chemo/ipi; Chemotherapy; Placebo
- Arms
- Chemo · Other
- REGN2810+Chemo Part 1 · Experimental
- REGN2810+AbbrevChemo+ipi · Experimental
- Placebo+Chemo · Experimental
- REGN2810+Chemo Part 2 · Experimental
- Enrollment
- 789
- Primary outcomes
- Part 1: Overall Survival (OS)
- Part 2: OS
- Sponsor
- Regeneron Pharmaceuticals with Sanofi
- Start
- Mar 6, 2018
- Primary completion
- Feb 27, 2025
- Results posted
- Yes
- Registry record
- NCT03409614 · updated May 18, 2026
Publications
linked from the registry- Baramidze A, Makharadze T, Gogishvili M, Melkadze T, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Ag McIntyre D, Perez J, Kaul M, Quek RGW, Seebach F, Rietschel P, Pouliot JF. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 >/= 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial. Lung Cancer. 2024 Jul;193:107821. doi: 10.1016/j.lungcan.2024.107821. Epub 2024 May 13. PubMed 38820979
- Zhao B, Qi H, Wu J, Ma W. Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. J Thorac Oncol. 2023 Jul;18(7):e72-e73. doi: 10.1016/j.jtho.2023.04.001. No abstract available. PubMed 37348996
- Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li S, Li Y, Kaul M, Quek RGW, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. J Thorac Oncol. 2023 Jun;18(6):755-768. doi: 10.1016/j.jtho.2023.03.008. Epub 2023 Mar 29. PubMed 37001859
- Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Gessner C, Moreno-Jaime B, Passalacqua R, Li S, McGuire K, Kaul M, Paccaly A, Quek RGW, Gao B, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Gullo G, Rietschel P. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med. 2022 Nov;28(11):2374-2380. doi: 10.1038/s41591-022-01977-y. Epub 2022 Aug 25. PubMed 36008722